Employer profile
Madrigal Pharmaceuticals Inc
59 open roles indexed with location, benefit, and apply-link signals where available.
Open roles
Showing the most recent indexed roles for this employer.
-
Medical Science Liaison, North Atlantic
CT - Connecticut - Field
unspecified $195K-$239KMedical Science Liaison, North Atlantic CT - Connecticut - Field Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. MEDICAL SCIENCE LIAISON (MSL), MEDICAL AFFAIRS Field-Based Medical role reporting to a regional Field Director. The Madrigal MSL will build scientific partnerships with Healthcare Professionals and decision makers using evidence-based science and non-promotional scientific exchange. The MSL will serve as a point of contact for the latest scientific and clinical information regarding Madrigal's novel NASH research program to thought leaders, academic centers, community group practices and regional professional organizations. MSL will report external insights to better
-
Medical Science Liaison, Great Lakes
Detroit, MI
unspecified $195K-$239KMedical Science Liaison, Great Lakes Detroit, MI Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. MEDICAL SCIENCE LIAISON (MSL), MEDICAL AFFAIRS Field-Based Medical role reporting to a regional Field Director. The Madrigal MSL will build scientific partnerships with Healthcare Professionals and decision makers using evidence-based science and non-promotional scientific exchange. The MSL will serve as a point of contact for the latest scientific and clinical information regarding Madrigal's novel NASH research program to thought leaders, academic centers, community group practices and regional professional organizations. MSL will report external insights to better understand MASH diagnosis
-
Medical Science Liaison, Florida South
Miami, FL
unspecified $195K-$239KMedical Science Liaison, Florida South Miami, FL Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. MEDICAL SCIENCE LIAISON (MSL), MEDICAL AFFAIRS Field-Based Medical role reporting to a regional Field Director. The Madrigal MSL will build scientific partnerships with Healthcare Professionals and decision makers using evidence-based science and non-promotional scientific exchange. The MSL will serve as a point of contact for the latest scientific and clinical information regarding Madrigal's novel NASH research program to thought leaders, academic centers, community group practices and regional professional organizations. MSL will report external insights to better understand MASH diagnosis
-
Clinical Practice Liaison, Northern California
San Francisco, California - Field
unspecified $155K-$190KClinical Practice Liaison, Northern California San Francisco, California - Field Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Clinical Practice Liaison (CPL) plays a vital field-based role within Madrigal's Medical Affairs team, focused on improving the standard of care for patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH). The CPL will proactively engage healthcare professionals (HCPs) to provide guideline-based, non-promotional disease education on the identification, diagnosis, and management of MASH. This role centers on empowering clinical practices to adopt evidence-based care pathways, integrate non-invasive diagnostic tools, enhance risk stratification, and collaborate in multidisciplinary care models.
-
Associate Director, Data Enablement
2 Locations
unspecified $180K-$220KAssociate Director, Data Enablement 2 Locations Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Associate Director, Data Enablement is a client-facing data partner for Madrigal's Commercial organization, ensuring strategic and operational data needs are met across requirements, integration, acquisition, and day-to-day operations. Reporting to the Director, Data Enablement, this role spans all commercial data domains - Market Access, Trade, Patient Services (MPS), Marketing, and Sales - translating business needs into governed, analytics-ready data and safeguarding the continuity of the data that powers Commercial decision-making. This is a hands-on role for someone fluent in
-
Area Business Manager, Columbia, SC
SC - South Carolina - Field
unspecified $158K-$192KArea Business Manager, Columbia, SC SC - South Carolina - Field Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. In this role, the Area Business Manager (ABM) will develop the territory business plan to achieve/exceed business and sales goals. You will work closely with your team and others across the organization to execute and deliver sales results that contribute to the overall performance, culture, and success of the organization. The Area Business Manager will play a pivotal role in introducing Madrigal and our potential groundbreaking first-to-market product addressing a significant patient unmet need. As
-
Area Business Manager, Asheville, NC
NC - North Carolina - Field
unspecified $158K-$192KArea Business Manager, Asheville, NC NC - North Carolina - Field Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. In this role, the Area Business Manager (ABM) will develop the territory business plan to achieve/exceed business and sales goals. You will work closely with your team and others across the organization to execute and deliver sales results that contribute to the overall performance, culture, and success of the organization. The Area Business Manager will play a pivotal role in introducing Madrigal and our potential groundbreaking first-to-market product addressing a significant patient unmet need. As
-
Senior Administrative Assistant
MA - Waltham - Office
unspecified $91K-$111KSenior Administrative Assistant MA - Waltham - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. We are seeking a proactive, highly organized Senior Administrative Assistant to support key business operations, communications, and team coordination activities. This role requires a strong blend of traditional administrative expertise (calendar, travel, and expense support) along with light project management, team collaboration, and event planning skills. The ideal candidate will demonstrate sound judgment, discretion, and an ability to operate independently in a dynamic, fast-paced environment. Key Responsibilities · Manage complex calendars, prioritize and schedule meetings (internal and external),
-
Senior Director, Global Safety Physician
2 Locations
unspecified $318K-$389KSenior Director, Global Safety Physician 2 Locations Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Senior Director, Global Safety Physician provides medical safety leadership for assigned investigational and marketed products, with accountability for medically sound safety assessments, ongoing benefit-risk evaluation, and timely recommendations to protect patients. The role partners closely with safety scientists, Clinical Development, Regulatory Affairs, Biostatistics, and Clinical Operations, contributing to regulatory submissions and safety governance. The Senior Director serves as a medical expert and strategic advisor for assigned programs, leading medical safety strategy, reviewing critical safety documents, and supporting health
-
Associate Director, Trial Master File Operations
2 Locations
unspecified $179K-$206KAssociate Director, Trial Master File Operations 2 Locations Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Associate Director (AD) TMF Operations will be responsible for leading day-to-day TMF operational strategy, oversight, inspection readiness, sponsor QC oversight, metrics management, issue escalation, and governance across the TMF operating model. This role will ensure that TMF processes are consistently executed, inspection-ready, and aligned with regulatory expectations, internal standards, study needs, and sponsor oversight obligations. This individual will serve as the primary business owner for TMF operational quality and will manage FSP resources supporting TMF activities. The
-
Vice President, IT Resilience & Trust
PA - Conshohocken - Office
unspecified $295K-$295KVice President, IT Resilience & Trust PA - Conshohocken - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Vice President, IT Resilience & Trust is a strategic and operational technology executive responsible for ensuring Madrigal's technology environment is reliable, resilient, secure, compliant, and able to scale with the business. As Madrigal continues to grow, expand internationally, and adopt new technologies at increasing speed, the technology foundation supporting the company is becoming more complex, interconnected, and critical to business performance. This leader will bring together Infrastructure & Reliability, Cybersecurity, and Technology Compliance under
-
VP, Commercial & Medical Affairs IT Business Partner
PA - Conshohocken - Office
unspecified $295K-$295KVP, Commercial & Medical Affairs IT Business Partner PA - Conshohocken - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Vice President, Commercial & Medical Affairs IT Business Partner will lead Madrigal's Commercial and Medical Affairs IT Business Partnership, supporting the company's global Commercial and Medical Affairs organizations. This role will serve as the senior IT partner to the Commercial and Medical Affairs executive leadership teams, translating functional strategy into technology roadmaps, portfolio priorities, operating capabilities, and delivery outcomes. As Madrigal continues to scale as a commercial-stage company, the technology needs across
-
Senior Director, Clinical Operations
PA - Conshohocken - Office
unspecified $262K-$307KSenior Director, Clinical Operations PA - Conshohocken - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Senior Director, Clinical Operations provides strategic and operational leadership for the planning, execution, and oversight of global Phase I-IV clinical trials and clinical development programs. This role is accountable for the successful delivery of one or more complex clinical programs from study start-up through closeout, ensuring execution against timelines, quality, budget, and corporate objectives while maintaining compliance with global regulatory requirements. The Senior Director, Clinical Operations will drive operational strategy across a portfolio of studies while
-
Area Business Manager, Chicago North
IL - Illinois - Field
unspecified $158K-$192KArea Business Manager, Chicago North IL - Illinois - Field Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. In this role, the Area Business Manager (ABM) will develop the territory business plan to achieve/exceed business and sales goals. You will work closely with your team and others across the organization to execute and deliver sales results that contribute to the overall performance, culture, and success of the organization. The Area Business Manager will play a pivotal role in introducing Madrigal and our potential groundbreaking first-to-market product addressing a significant patient unmet need. As an
-
Regional Sales Director- Pacific Northwest
WA - Washington - Field
unspecified $214K-$262KRegional Sales Director- Pacific Northwest WA - Washington - Field Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. Opportunity and Summary of Position: In this role, the Regional Sales Director will develop the regional business strategy, and hire and lead a team of high-performing Area Business Managers to achieve/exceed business and sales goals. You will work closely with commercial leadership and collaborate with other senior leaders across the organization to develop and execute strategies and initiatives that contribute to the overall performance, culture and success of the organization. The Regional Sales Director will be
-
Area Business Manager, Orange County South
CA - California - Field
unspecified $158K-$192KArea Business Manager, Orange County South CA - California - Field Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. In this role, the Area Business Manager (ABM) will develop the territory business plan to achieve/exceed business and sales goals. You will work closely with your team and others across the organization to execute and deliver sales results that contribute to the overall performance, culture, and success of the organization. The Area Business Manager will play a pivotal role in introducing Madrigal and our potential groundbreaking first-to-market product addressing a significant patient unmet need. As
-
Senior Manager – Accounting
PA - Conshohocken - Office
unspecified $139K-$169KSenior Manager – Accounting PA - Conshohocken - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. We are seeking a Senior Manager, Accounting to join our finance team. The ideal candidate will have a strong fundamental understanding of U.S. GAAP and experience managing general ledger accounting and financial close activities. Experience within the pharmaceutical, biotechnology, or life sciences industry is strongly preferred. The Senior Manager, Accounting will play a key role in overseeing the monthly, quarterly, and annual close process and ensuring the accuracy, completeness, and integrity of the Company's financial records. This
-
Director, Drug Product siRNA SME
PA - Conshohocken - Office
unspecified $204K-$249KDirector, Drug Product siRNA SME PA - Conshohocken - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Director, Drug Product SME is an experienced scientific leader, with responsibility for advancing the CMC development of Madrigal's siRNA/oligonucleotide and small molecule portfolio. This role focuses on drug product formulation and process development, ensuring preclinical and clinical studies are supported with phase appropriate quality investigational medicinal product, delivered on time and guided by scientific rigor, risk assessment and data-driven decision-making. As a key member of CMC development project teams within Technical Operations, this leader will
-
Senior Treasury Analyst
MA - Waltham - Office
unspecified $103K-$126KSenior Treasury Analyst MA - Waltham - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. Reporting to the Associate Director, Treasury, the Senior Treasury Analyst will play a key role in optimizing global liquidity, enhancing treasury operations, and strengthening financial controls across the organization. This role supports a multi-entity, multi-currency environment and partners closely with FP&A, Accounting, Tax, Legal, Internal Audit and banking partners to deliver scalable treasury processes, manage financial and foreign currency risk, and support the company's continued growth. The Senior Treasury Analyst will also contribute to the governance and accounting
-
Director, Drug Product Small Molecule SME
PA - Conshohocken - Office
unspecified $204K-$250KDirector, Drug Product Small Molecule SME PA - Conshohocken - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. Position Summary The Director Drug Product SME is an experienced scientific and technical leader, accountable for defining and driving the CMC drug product development strategy for Madrigal's small molecule portfolio. This role leads drug product formulation and process development, ensuring preclinical and clinical studies are supported with phase-appropriate quality investigational medicinal product, delivered on time and guided by scientific rigor, risk assessment and data-driven decision-making. The Director is accountable for leading at least one cross-functional